These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36781600)

  • 1. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
    Wang F
    Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
    Huang X; Zhang G; Tang T; Liang T
    Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
    Huang X; Tang T; Zhang G; Liang T
    Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development.
    Lu T; Xu R; Wang CH; Zhao JY; Peng B; Wang J; Zhang LY
    Front Genet; 2022; 13():853113. PubMed ID: 35734437
    [No Abstract]   [Full Text] [Related]  

  • 5. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
    Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
    Front Immunol; 2021; 12():738435. PubMed ID: 34603319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
    Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
    Front Immunol; 2022; 13():773264. PubMed ID: 35185876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
    Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
    Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
    [No Abstract]   [Full Text] [Related]  

  • 8. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
    Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
    Front Immunol; 2021; 12():709986. PubMed ID: 34512630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma.
    Li HX; Liu TR; Tu ZX; Xie CB; Wen WP; Sun W
    Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development.
    Ye L; Wang L; Yang J; Hu P; Zhang C; Tong S; Liu Z; Tian D
    J Transl Med; 2021 Aug; 19(1):352. PubMed ID: 34404444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine.
    Hu J; Mo Z
    Math Biosci Eng; 2023 Jan; 20(2):2157-2182. PubMed ID: 36899527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
    You W; Ouyang J; Cai Z; Chen Y; Wu X
    Front Immunol; 2022; 13():827506. PubMed ID: 35874675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8 + T cell-based molecular subtypes with heterogeneous immune landscapes and clinical significance in acute myeloid leukemia.
    Zhong F; Yao F; Jiang J; Yu X; Liu J; Huang B; Wang X
    Inflamm Res; 2024 Mar; 73(3):329-344. PubMed ID: 38195768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma.
    Zhang S; Li S; Wei Y; Xiong Y; Liu Q; Hu Z; Zeng Z; Tang F; Ouyang Y
    Front Cell Dev Biol; 2022; 10():879278. PubMed ID: 35846349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of tumor-antigen signatures and immune subtypes for messenger RNA vaccine selection in advanced clear cell renal cell carcinoma.
    Xu Z; Wu Y; Chen X; Jin B
    Surgery; 2024 Sep; 176(3):785-797. PubMed ID: 38851900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine.
    Zheng X; Xu H; Yi X; Zhang T; Wei Q; Li H; Ai J
    Mol Cancer; 2021 Dec; 20(1):160. PubMed ID: 34872584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma.
    Xu H; Zheng X; Zhang S; Yi X; Zhang T; Wei Q; Li H; Ai J
    Mol Cancer; 2021 Dec; 20(1):159. PubMed ID: 34872567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular subtyping of acute myeloid leukemia through ferroptosis signatures predicts prognosis and deciphers the immune microenvironment.
    Fu D; Zhang B; Wu S; Feng J; Jiang H
    Front Cell Dev Biol; 2023; 11():1207642. PubMed ID: 37691822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine.
    Ping H; Yu W; Gong X; Tong X; Lin C; Chen Z; Cai C; Guo K; Ke H
    Invest New Drugs; 2022 Dec; 40(6):1173-1184. PubMed ID: 35962880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine.
    Tan H; Yu T; Liu C; Wang Y; Jing F; Ding Z; Liu J; Shi H
    Cancer Med; 2022 Dec; 11(23):4656-4672. PubMed ID: 35593226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.